TABLE 2.
Diagnostic performance of ESAT6-CFP10 skin test, QuantiFERON-TB Gold In-Tube test (≥0.35 IU/mL), and tuberculin skin test (≥5 mm)a
| Parameter | EC skin test |
QFT (≥0.35 IU/mL) |
TST (≥5 mm) |
|||
|---|---|---|---|---|---|---|
| n/N | Estimate (95% CI) | n/N | Estimate (95% CI) | n/N | Estimate (95% CI) | |
| Sensitivity | ||||||
| TST positive participants | 40/59 | 67.8 (54.4–79.4) | 43/56 | 76.8 (63.6–87.0) | ||
| BCG vaccinated | 21/30 | 70.0 (50.6–85.3) | 22/29 | 75.9 (56.5–89.7) | ||
| Unvaccinated | 18/28 | 64.3 (44.1–81.4) | 21/27 | 77.8 (57.7–91.4) | ||
| QFT positive participants | 51/89 | 57.3 (46.4–67.7) | 43/89 | 48.3 (37.6–59.2) | ||
| BCG vaccinated | 26/40 | 65.0 (48.3–79.4) | 22/40 | 55.0 (38.5–70.7) | ||
| Unvaccinated | 25/49 | 51.0 (36.3–65.6) | 21/49 | 42.9 (28.8–57.8) | ||
| TST and QFT positive | 35/43 | 81.4 (66.6–91.6) | ||||
| BCG vaccinated | 19/22 | 86.4 (65.1–97.1) | ||||
| Unvaccinated | 16/21 | 76.2 (52.8–91.8) | ||||
| Specificity | ||||||
| TST negative participants | 273/291 | 93.8 (90.4–96.3) | 241/287 | 84.0 (78.0–87.0) | ||
| BCG vaccinated | 119/128 | 93.0 (87.1–96.7) | 109/127 | 85.8 (78.5–91.4) | ||
| Unvaccinated | 153/162 | 94.4 (89.7–97.4) | 131/159 | 82.4 (75.6–88.0) | ||
| QFT negative participants | 251/254 | 98.8 (96.6–99.8) | 241/254 | 94.9 (91.4–97.2) | ||
| BCG vaccinated | 114/116 | 98.3 (93.9–99.8) | 109/116 | 94.0 (88.0–97.5) | ||
| Unvaccinated | 136/137 | 99.3 (96.0–100.0) | 131/137 | 95.6 (90.7–98.4) | ||
| TST and QFT negative | 240/241 | 99.6 (97.7–100.0) | ||||
| BCG vaccinated | 108/109 | 99.1 (95.0–100.0) | ||||
| Unvaccinated | 131/131 | 100.0 (97.2–100.0) | ||||
a
EC, ESAT6-CFP10; TST, tuberculin skin test; QFT, QuantiFERON-TB Gold In-Tube test; n/N, number/total number; CI, confidence interval; BCG, bacillus Calmette-Guerin.